DIAMOND BIOFUND INC Net Assets
DIAMOND BIOFUND INC net assets. Based on the latest financial reports, DIAMOND BIOFUND INC (6901) has net assets worth NT$9.22 Billion TWD (≈ $290.51 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$9.36 Billion ≈ $294.85 Million USD) and total liabilities (NT$137.79 Million ≈ $4.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 6901 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$9.22 Billion |
| % of Total Assets | 98.53% |
| Annual Growth Rate | 20.5% |
| 5-Year Change | -11.27% |
| 10-Year Change | N/A |
| Growth Volatility | 76.0 |
Net Assets of DIAMOND BIOFUND INC (2019–2025)
Net assets of DIAMOND BIOFUND INC from 2019 to 2025. This chart illustrates how DIAMOND BIOFUND INC's net assets have evolved over time, based on quarterly financial data. See DIAMOND BIOFUND INC balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for DIAMOND BIOFUND INC (2019–2025)
The table below shows the annual net assets of DIAMOND BIOFUND INC from 2019 to 2025. For live market cap and overall valuation, see market cap of DIAMOND BIOFUND INC.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$9.22 Billion ≈ $290.51 Million |
-11.11% |
| 2024-12-31 | NT$10.37 Billion ≈ $326.81 Million |
-19.35% |
| 2023-12-31 | NT$12.86 Billion ≈ $405.22 Million |
+16.39% |
| 2022-12-31 | NT$11.05 Billion ≈ $348.15 Million |
+6.34% |
| 2021-12-31 | NT$10.39 Billion ≈ $327.41 Million |
+14.20% |
| 2020-12-31 | NT$9.10 Billion ≈ $286.71 Million |
+202.26% |
| 2019-12-31 | NT$3.01 Billion ≈ $94.85 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DIAMOND BIOFUND INC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68370600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
DIAMOND BIOFUND INC Net Assets Breakdown (December 2025)
DIAMOND BIOFUND INC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$8.53 Billion | 92.48% |
| Other Comprehensive Income | NT$44.91 Million | 0.49% |
| Other Components | NT$2.84 Billion | 30.81% |
| Total Equity | NT$9.22 Billion | 100.00% |
DIAMOND BIOFUND INC Competitors by Market Cap
The table below lists competitors of DIAMOND BIOFUND INC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Artos Indonesia Tbk PT
JK:ARTO
|
$404.49 Million |
|
Tibet Aim Pharm Inc
SHE:002826
|
$404.86 Million |
|
Abm Investama Tbk
JK:ABMM
|
$404.92 Million |
|
Nanjing CEC Environmental Protect
SHE:300172
|
$405.01 Million |
|
YTL Hospitality REIT
KLSE:5109
|
$404.38 Million |
|
Verra Mobility Corp
NASDAQ:VRRM
|
$404.27 Million |
|
Zota Health Care LImited
NSE:ZOTA
|
$404.21 Million |
|
APAC Opto Electronics
TWO:4908
|
$404.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DIAMOND BIOFUND INC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,373,048,000 to 9,220,875,000, a change of -1,152,173,000 (-11.1%).
- Net loss of 1,174,732,000 reduced equity.
- New share issuances of 15,833,000 increased equity.
- Other comprehensive income increased equity by 44,906,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.17 Billion | -12.74% |
| Share Issuances | NT$15.83 Million | +0.17% |
| Other Comprehensive Income | NT$44.91 Million | +0.49% |
| Other Changes | NT$-38.18 Million | -0.41% |
| Total Change | NT$- | -11.11% |
Book Value vs Market Value Analysis
This analysis compares DIAMOND BIOFUND INC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.37x to 1.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$4.46 | NT$15.05 | x |
| 2020-12-31 | NT$9.11 | NT$15.05 | x |
| 2021-12-31 | NT$10.88 | NT$15.05 | x |
| 2022-12-31 | NT$14.29 | NT$15.05 | x |
| 2023-12-31 | NT$16.51 | NT$15.05 | x |
| 2024-12-31 | NT$12.20 | NT$15.05 | x |
| 2025-12-31 | NT$10.82 | NT$15.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DIAMOND BIOFUND INC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: -0.00x
- • Equity Multiplier: 1.01x
- Recent ROE (-12.74%) is below the historical average (4.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -12.32% | 0.00% | 0.00x | 1.02x | NT$-671.94 Million |
| 2020 | 66.92% | 0.00% | 0.00x | 1.02x | NT$5.18 Billion |
| 2021 | 27.44% | 0.00% | 0.00x | 1.02x | NT$1.81 Billion |
| 2022 | 7.22% | 0.00% | 0.00x | 1.01x | NT$-307.25 Million |
| 2023 | -20.09% | 0.00% | 0.00x | 1.01x | NT$-3.87 Billion |
| 2024 | -24.27% | 0.00% | 0.00x | 1.03x | NT$-3.56 Billion |
| 2025 | -12.74% | 0.00% | 0.00x | 1.01x | NT$-2.10 Billion |
Industry Comparison
This section compares DIAMOND BIOFUND INC's net assets metrics with peer companies in the Asset Management industry.
No peer company data available for comparison.
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.